High-throughput, human-derived blood–brain barrier (BBB) screening platform that delivers rapid, high-fidelity predictions of brain penetrance, efficacy, and toxicity. Modular system enables parallel compound testing to accelerate CNS drug discovery for researchers and biotech targeting glioblastoma, neuro‑inflammation, and neurodegeneration.